Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2018 Mar;364(3):485-493. doi: 10.1124/jpet.117.245647. Epub 2018 Jan 8.

PMID:
29311110
2.

β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Ganesh S, Shui X, Craig KP, Koser ML, Chopda GR, Cyr WA, Lai C, Dudek H, Wang W, Brown BD, Abrams MT.

Mol Cancer Ther. 2018 Feb;17(2):544-553. doi: 10.1158/1535-7163.MCT-17-0605. Epub 2017 Dec 27.

PMID:
29282298
3.

Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Ganesh S, Koser ML, Cyr WA, Chopda GR, Tao J, Shui X, Ying B, Chen D, Pandya P, Chipumuro E, Siddiquee Z, Craig K, Lai C, Dudek H, Monga SP, Wang W, Brown BD, Abrams MT.

Mol Cancer Ther. 2016 Sep;15(9):2143-54. doi: 10.1158/1535-7163.MCT-16-0309. Epub 2016 Jul 7.

4.

Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.

Chopda GR, Parge V, Thakur GA, Gatley SJ, Makriyannis A, Paronis CA.

J Pharmacol Exp Ther. 2016 Aug;358(2):334-41. doi: 10.1124/jpet.116.232132. Epub 2016 May 26.

5.

Diuretic effects of cannabinoid agonists in mice.

Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, Paronis CA.

Eur J Pharmacol. 2013 Dec 5;721(1-3):64-9. doi: 10.1016/j.ejphar.2013.09.053. Epub 2013 Oct 5.

Supplemental Content

Loading ...
Support Center